Chudasama, V; Maruani, A; Caddick, S; (2016) Recent advances in the construction of antibody–drug conjugates. Nature Chemistry , 8 pp. 114-119. 10.1038/nchem.2415.

Preview

Text ADC Perspective.pdf - Submitted Version Download (490kB) | Preview

Abstract

Antibody-drug conjugates (ADCs) are derived from antibodies covalently attached to highly potent drugs using a variety of conjugation and linker technologies. This class of therapeutic conceptually combines the exquisite specificity of antibodies (i.e. enabling discrimination between healthy and diseased tissue) with the cell-killing ability of potent cytotoxic drugs. This powerful and exciting class of targeted therapy has shown considerable promise in the treatment of various cancers with two US Food and Drug Administration (FDA) approved ADCs currently on the market (i.e. Adcetris™ and Kadcyla™) and ca. 40 ADCs currently undergoing clinical evaluation. However, in order for ADCs to deliver their full potential, sophisticated site-specific conjugation technologies to connect the drug to the antibody are vital. This perspective discusses the strategies currently used for the site-specific construction of ADCs and appraises their merits and disadvantages.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item